Loading…
VEGF and angiopoietin signaling in tumor angiogenesis and metastasis
Solid tumors require blood vessels for growth and dissemination, and lymphatic vessels as additional conduits for metastatic spread. The identification of growth factor receptor pathways regulating angiogenesis has led to the clinical approval of the first antiangiogenic molecules targeted against t...
Saved in:
Published in: | Trends in molecular medicine 2011-07, Vol.17 (7), p.347-362 |
---|---|
Main Authors: | , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c482t-76b68a7febc2ca25d0b6dd1bf28093fdaf1dcc5767bec9108dabcdcebef4f8543 |
---|---|
cites | cdi_FETCH-LOGICAL-c482t-76b68a7febc2ca25d0b6dd1bf28093fdaf1dcc5767bec9108dabcdcebef4f8543 |
container_end_page | 362 |
container_issue | 7 |
container_start_page | 347 |
container_title | Trends in molecular medicine |
container_volume | 17 |
creator | Saharinen, Pipsa Eklund, Lauri Pulkki, Kristina Bono, Petri Alitalo, Kari |
description | Solid tumors require blood vessels for growth and dissemination, and lymphatic vessels as additional conduits for metastatic spread. The identification of growth factor receptor pathways regulating angiogenesis has led to the clinical approval of the first antiangiogenic molecules targeted against the vascular endothelial growth factor (VEGF)–VEGF receptor (VEGFR)-2 pathway. However, in many cases resistance to anti-VEGF–VEGFR therapy occurs, and thus far the clinical benefit has been limited to only modest improvements in overall survival. Therefore, novel treatment modalities are required. Here, we discuss the members of the VEGF–VEGFR family as well as the angiopoietin growth factors and their Tie receptors as potential novel targets for antiangiogenic and antilymphangiogenic therapies. |
doi_str_mv | 10.1016/j.molmed.2011.01.015 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_878031785</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S1471491411000256</els_id><sourcerecordid>878031785</sourcerecordid><originalsourceid>FETCH-LOGICAL-c482t-76b68a7febc2ca25d0b6dd1bf28093fdaf1dcc5767bec9108dabcdcebef4f8543</originalsourceid><addsrcrecordid>eNqFkUtLxDAQx4Movr-ByN487ZrpK9mLIL5B8OADbyFNpkvWtlkzrbDf3tSqBy_ChEyY_3-G_IaxI-Az4FCcLmeNrxu0s4QDzPgQ-QbbhUzANJvPXzd_c8h22B7RkkeFEHKb7SSQSShSscsuX65urie6tfEsnF95h51rJ-QWra5du5jER9c3Poz1BbZIjr4MDXaaYjg6YFuVrgkPv-999nx99XRxO71_uLm7OL-fmkwm3VQUZSG1qLA0idFJbnlZWAtllUg-TyurK7DG5KIQJZo5cGl1aazBEqusknmW7rOTse8q-PceqVONI4N1rVv0PSkpJE9ByDwqs1FpgicKWKlVcI0OawVcDfjUUo341IBP8SEG2_H3gL4caj-mH15RcDYKMH7zw2FQZBy2Bq0LaDplvftvwt8GJmJ2RtdvuEZa-j5E8KRAUaK4ehxWOGwQgHOe5EX6CREOmV8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>878031785</pqid></control><display><type>article</type><title>VEGF and angiopoietin signaling in tumor angiogenesis and metastasis</title><source>ScienceDirect Freedom Collection 2022-2024</source><creator>Saharinen, Pipsa ; Eklund, Lauri ; Pulkki, Kristina ; Bono, Petri ; Alitalo, Kari</creator><creatorcontrib>Saharinen, Pipsa ; Eklund, Lauri ; Pulkki, Kristina ; Bono, Petri ; Alitalo, Kari</creatorcontrib><description>Solid tumors require blood vessels for growth and dissemination, and lymphatic vessels as additional conduits for metastatic spread. The identification of growth factor receptor pathways regulating angiogenesis has led to the clinical approval of the first antiangiogenic molecules targeted against the vascular endothelial growth factor (VEGF)–VEGF receptor (VEGFR)-2 pathway. However, in many cases resistance to anti-VEGF–VEGFR therapy occurs, and thus far the clinical benefit has been limited to only modest improvements in overall survival. Therefore, novel treatment modalities are required. Here, we discuss the members of the VEGF–VEGFR family as well as the angiopoietin growth factors and their Tie receptors as potential novel targets for antiangiogenic and antilymphangiogenic therapies.</description><identifier>ISSN: 1471-4914</identifier><identifier>EISSN: 1471-499X</identifier><identifier>DOI: 10.1016/j.molmed.2011.01.015</identifier><identifier>PMID: 21481637</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Angiogenesis Inhibitors - metabolism ; Angiopoietins - antagonists & inhibitors ; Angiopoietins - genetics ; Animals ; Gene Expression Regulation, Neoplastic ; Humans ; Lymphatic Vessels - metabolism ; Models, Animal ; Neoplasm Metastasis - genetics ; Neoplasm Metastasis - pathology ; Pathology ; Receptors, TIE - metabolism ; Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors ; Signal Transduction ; Vascular Endothelial Growth Factor A - antagonists & inhibitors ; Vascular Endothelial Growth Factor A - genetics</subject><ispartof>Trends in molecular medicine, 2011-07, Vol.17 (7), p.347-362</ispartof><rights>Elsevier Ltd</rights><rights>2011 Elsevier Ltd</rights><rights>Copyright © 2011 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c482t-76b68a7febc2ca25d0b6dd1bf28093fdaf1dcc5767bec9108dabcdcebef4f8543</citedby><cites>FETCH-LOGICAL-c482t-76b68a7febc2ca25d0b6dd1bf28093fdaf1dcc5767bec9108dabcdcebef4f8543</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21481637$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Saharinen, Pipsa</creatorcontrib><creatorcontrib>Eklund, Lauri</creatorcontrib><creatorcontrib>Pulkki, Kristina</creatorcontrib><creatorcontrib>Bono, Petri</creatorcontrib><creatorcontrib>Alitalo, Kari</creatorcontrib><title>VEGF and angiopoietin signaling in tumor angiogenesis and metastasis</title><title>Trends in molecular medicine</title><addtitle>Trends Mol Med</addtitle><description>Solid tumors require blood vessels for growth and dissemination, and lymphatic vessels as additional conduits for metastatic spread. The identification of growth factor receptor pathways regulating angiogenesis has led to the clinical approval of the first antiangiogenic molecules targeted against the vascular endothelial growth factor (VEGF)–VEGF receptor (VEGFR)-2 pathway. However, in many cases resistance to anti-VEGF–VEGFR therapy occurs, and thus far the clinical benefit has been limited to only modest improvements in overall survival. Therefore, novel treatment modalities are required. Here, we discuss the members of the VEGF–VEGFR family as well as the angiopoietin growth factors and their Tie receptors as potential novel targets for antiangiogenic and antilymphangiogenic therapies.</description><subject>Angiogenesis Inhibitors - metabolism</subject><subject>Angiopoietins - antagonists & inhibitors</subject><subject>Angiopoietins - genetics</subject><subject>Animals</subject><subject>Gene Expression Regulation, Neoplastic</subject><subject>Humans</subject><subject>Lymphatic Vessels - metabolism</subject><subject>Models, Animal</subject><subject>Neoplasm Metastasis - genetics</subject><subject>Neoplasm Metastasis - pathology</subject><subject>Pathology</subject><subject>Receptors, TIE - metabolism</subject><subject>Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors</subject><subject>Signal Transduction</subject><subject>Vascular Endothelial Growth Factor A - antagonists & inhibitors</subject><subject>Vascular Endothelial Growth Factor A - genetics</subject><issn>1471-4914</issn><issn>1471-499X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><recordid>eNqFkUtLxDAQx4Movr-ByN487ZrpK9mLIL5B8OADbyFNpkvWtlkzrbDf3tSqBy_ChEyY_3-G_IaxI-Az4FCcLmeNrxu0s4QDzPgQ-QbbhUzANJvPXzd_c8h22B7RkkeFEHKb7SSQSShSscsuX65urie6tfEsnF95h51rJ-QWra5du5jER9c3Poz1BbZIjr4MDXaaYjg6YFuVrgkPv-999nx99XRxO71_uLm7OL-fmkwm3VQUZSG1qLA0idFJbnlZWAtllUg-TyurK7DG5KIQJZo5cGl1aazBEqusknmW7rOTse8q-PceqVONI4N1rVv0PSkpJE9ByDwqs1FpgicKWKlVcI0OawVcDfjUUo341IBP8SEG2_H3gL4caj-mH15RcDYKMH7zw2FQZBy2Bq0LaDplvftvwt8GJmJ2RtdvuEZa-j5E8KRAUaK4ehxWOGwQgHOe5EX6CREOmV8</recordid><startdate>20110701</startdate><enddate>20110701</enddate><creator>Saharinen, Pipsa</creator><creator>Eklund, Lauri</creator><creator>Pulkki, Kristina</creator><creator>Bono, Petri</creator><creator>Alitalo, Kari</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20110701</creationdate><title>VEGF and angiopoietin signaling in tumor angiogenesis and metastasis</title><author>Saharinen, Pipsa ; Eklund, Lauri ; Pulkki, Kristina ; Bono, Petri ; Alitalo, Kari</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c482t-76b68a7febc2ca25d0b6dd1bf28093fdaf1dcc5767bec9108dabcdcebef4f8543</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Angiogenesis Inhibitors - metabolism</topic><topic>Angiopoietins - antagonists & inhibitors</topic><topic>Angiopoietins - genetics</topic><topic>Animals</topic><topic>Gene Expression Regulation, Neoplastic</topic><topic>Humans</topic><topic>Lymphatic Vessels - metabolism</topic><topic>Models, Animal</topic><topic>Neoplasm Metastasis - genetics</topic><topic>Neoplasm Metastasis - pathology</topic><topic>Pathology</topic><topic>Receptors, TIE - metabolism</topic><topic>Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors</topic><topic>Signal Transduction</topic><topic>Vascular Endothelial Growth Factor A - antagonists & inhibitors</topic><topic>Vascular Endothelial Growth Factor A - genetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Saharinen, Pipsa</creatorcontrib><creatorcontrib>Eklund, Lauri</creatorcontrib><creatorcontrib>Pulkki, Kristina</creatorcontrib><creatorcontrib>Bono, Petri</creatorcontrib><creatorcontrib>Alitalo, Kari</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Trends in molecular medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Saharinen, Pipsa</au><au>Eklund, Lauri</au><au>Pulkki, Kristina</au><au>Bono, Petri</au><au>Alitalo, Kari</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>VEGF and angiopoietin signaling in tumor angiogenesis and metastasis</atitle><jtitle>Trends in molecular medicine</jtitle><addtitle>Trends Mol Med</addtitle><date>2011-07-01</date><risdate>2011</risdate><volume>17</volume><issue>7</issue><spage>347</spage><epage>362</epage><pages>347-362</pages><issn>1471-4914</issn><eissn>1471-499X</eissn><abstract>Solid tumors require blood vessels for growth and dissemination, and lymphatic vessels as additional conduits for metastatic spread. The identification of growth factor receptor pathways regulating angiogenesis has led to the clinical approval of the first antiangiogenic molecules targeted against the vascular endothelial growth factor (VEGF)–VEGF receptor (VEGFR)-2 pathway. However, in many cases resistance to anti-VEGF–VEGFR therapy occurs, and thus far the clinical benefit has been limited to only modest improvements in overall survival. Therefore, novel treatment modalities are required. Here, we discuss the members of the VEGF–VEGFR family as well as the angiopoietin growth factors and their Tie receptors as potential novel targets for antiangiogenic and antilymphangiogenic therapies.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>21481637</pmid><doi>10.1016/j.molmed.2011.01.015</doi><tpages>16</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1471-4914 |
ispartof | Trends in molecular medicine, 2011-07, Vol.17 (7), p.347-362 |
issn | 1471-4914 1471-499X |
language | eng |
recordid | cdi_proquest_miscellaneous_878031785 |
source | ScienceDirect Freedom Collection 2022-2024 |
subjects | Angiogenesis Inhibitors - metabolism Angiopoietins - antagonists & inhibitors Angiopoietins - genetics Animals Gene Expression Regulation, Neoplastic Humans Lymphatic Vessels - metabolism Models, Animal Neoplasm Metastasis - genetics Neoplasm Metastasis - pathology Pathology Receptors, TIE - metabolism Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors Signal Transduction Vascular Endothelial Growth Factor A - antagonists & inhibitors Vascular Endothelial Growth Factor A - genetics |
title | VEGF and angiopoietin signaling in tumor angiogenesis and metastasis |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T20%3A18%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=VEGF%20and%20angiopoietin%20signaling%20in%20tumor%20angiogenesis%20and%20metastasis&rft.jtitle=Trends%20in%20molecular%20medicine&rft.au=Saharinen,%20Pipsa&rft.date=2011-07-01&rft.volume=17&rft.issue=7&rft.spage=347&rft.epage=362&rft.pages=347-362&rft.issn=1471-4914&rft.eissn=1471-499X&rft_id=info:doi/10.1016/j.molmed.2011.01.015&rft_dat=%3Cproquest_cross%3E878031785%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c482t-76b68a7febc2ca25d0b6dd1bf28093fdaf1dcc5767bec9108dabcdcebef4f8543%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=878031785&rft_id=info:pmid/21481637&rfr_iscdi=true |